MILANO (ITALPRESS) – In Italy, around 40 fatal cases of anaphylactic shock are documented each year. More than half of these cases are triggered by food allergies, while the other half is due to insect stings. However, the actual numbers are uncertain and likely underestimated, as these figures only account for cases that make headlines. Many incidents go unreported due to a lack of national surveillance and categorization challenges encountered by emergency personnel. Experts urge the inclusion of anaphylactic reactions in the essential levels of care (LEA), the reclassification of the adrenaline auto-injector to Class A, the establishment of a network of reference allergy centers, standardized distribution of two auto-injectors across all regions, and the initiation of training campaigns for all health operators.
In Italy, access to life-saving devices varies significantly among regions. Many allergic patients at risk for anaphylactic shock lack access to adrenaline auto-injectors. Additionally, the classification of adrenaline under hospital regulations complicates patients’ ability to access this critical medication.
This topic was discussed during the institutional event “Anaphylaxis: Prevention and Awareness – A Commitment for Patient Safety,” organized by Food Allergy Italia APS in collaboration with the Parliamentary Intergroup on celiac disease, allergies, and AMFS, and supported by AAIITO (Italian Association of Territorial and Hospital Allergologists and Immunologists), SIAAIC (Italian Society of Allergology, Asthma, and Clinical Immunology), SIAIP (Italian Society of Pediatrics Allergology and Immunology), FOFI (Federation of Italian Pharmacists’ Orders), Federfarma, and FIPE (Italian Federation of Public Establishments). The event, organized by Cencora Pharmalex and realized with the unconditional support of Viatris, aimed to raise awareness about the current situation in Italy.
“Food Allergy Italia APS has always advocated for the rights of allergic individuals and to ensure maximum safety for patients at risk of anaphylaxis. In suitable institutional venues, we fight for the right to access life-saving medication and to inform and train both allergic individuals and all those involved in managing allergic patients concerning prevention strategies and the use of adrenaline auto-injectors,” stated Marcia Podestà, President of Food Allergy Italia APS at the opening of the event. “Even today, individuals in Italy die from anaphylaxis due to the absence of an effective prevention plan and barriers to accessing adrenaline auto-injectors for at-risk individuals. Despite EMA and AIFA recommendations, many Italian regions still do not guarantee the provision of two auto-injectors for each patient. These life-saving devices should be made available at local pharmacies to ensure prompt access in emergencies.”
The reclassification of life-saving auto-injectable adrenaline from the H category to Class A, allowing direct access via local pharmacies, would enable the National Health Service (SSN) to effectively meet patient needs. In addition to this crucial point, several other essential issues emerged during the debate that are vital for ensuring patient safety. Experts highlighted the need for optimal quantities of life-saving medication to manage anaphylaxis and to implement measures to prevent shortages, including establishing a network of referral allergy centers focusing on food allergies coordinated at a national level.
“The only way to respond promptly to anaphylactic shock is through the timely administration of auto-injectable adrenaline, which is recommended by EMA with two prescriptions. It is crucial that at-risk allergic patients have facilitated access to adrenaline auto-injectors for immediate self-administration in the event of a severe reaction,” explained Antonella Muraro, Director of the Regional Specialization Center for the Study and Treatment of Allergies and Food Intolerances at the University Hospital of Padua. “Patients must be prescribed appropriate emergency therapy, both in correct dosages and in the proper administration method.”
Further, prioritizing the early introduction of allergens in national public health initiatives and simultaneously increasing awareness about food allergies is essential. This can be achieved by providing adequate training for specialists, pediatricians, general practitioners, emergency room doctors, and pharmacists, as well as implementing public information campaigns for patients, families, food industry workers, restaurant owners, school meal operators, and workplaces, including enhancing training programs in hospitality schools.
Moreover, it remains crucial to update LEA to include diagnostic and therapeutic pathways for allergies and anaphylaxis, including life-saving treatments, and to adjust extra-LEA procedures to be tied to actual patient needs.
“Recognizing food allergies is the first step in ensuring necessary protection for allergic individuals. Today, we discussed ensuring all patients and at-risk individuals have immediate access to life-saving devices; this is a commitment we, alongside our parliamentary colleagues, intend to pursue,” said Elena Murelli, 10th Commission on Social Affairs, Health, Public and Private Labor, Social Security, Senate of the Republic, and President of the Parliamentary Intergroup on Celiac Disease, Food Allergies, and AMFS. “We are working on a motion that will call on the relevant authorities to increase awareness and training concerning food allergies, which are the leading cause of anaphylaxis outside hospitals, by introducing mandatory training courses on the use of adrenaline auto-injectors and ensuring equitable access for all at-risk patients, thereby reducing disparities between regions.”
– foto ufficio stampa PharmaLex Italy –
(ITALPRESS).
